-+ 0.00%
-+ 0.00%
-+ 0.00%

Global Brain makes additional investment in RegCell

PUBT·09/29/2026 02:19:41
Listen to the news
Global Brain makes additional investment in RegCell
  • Global Brain made an additional private investment in RegCell, a biotech developing epigenetic regulatory T-cell reprogramming therapies for autoimmune diseases.
  • RegCell converts pathogenic T cells into stable, antigen-specific Tregs, aiming to restore immune tolerance without genetic modification.
  • Funding came via Global Brain Flagship Fund IX, alongside 321FORCE Global Innovation Fund L.P. (321FORCE).
  • RegCell plans an IND filing, alongside Phase 2 proof-of-concept studies across two autoimmune indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global Brain Corp published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.